Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the Juvenile RCC Network

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1834-1838

  Malouf, G G ^a   Camparo, P ^b   Oudard, S ^c   Schleiermacher, G ^d   Theodore, C ^b   Rustine, A ^e   Dutcher, J ^e   Billemont, B ^f   Rixe, O ^g   Bompas, E ^h   Guillot, A ⁱ   Boccon Gibod, L ^j   Couturier, J ^d   Molinie V ^k   Escudier, B ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b FOCH HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSTITUT CURIE   (France)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f Hôpital Cochin ^*  (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ Institut de Cancerologie de la Loire   (France)

^j ARMAND TROUSSEAU HOSPITAL   (France)

^k SAINT JOSEPH HOSPITAL   (France)

more..

Author keywords

Interferon; Pediatric renal cell carcinoma; Sunitinib; Targeted agents; TFE3; Translocation renal cell carcinoma; Xp11.2

Indexed keywords

ALPHA INTERFERON; CYTOKINE; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; CHILD; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; XP11 TRANSLOCATION RENAL CELL CARCINOMA;

EID: 77953778637     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq029     Document Type: Article

References (18)

1. Argani P, Ladanyi M. Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions. In Eble JN, Sauter G, Epstein J, et al. (eds), Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IACR 2004; 37-38.
2. Komai Y, Fujiwara M, Fujii Y et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res 2009; 15: 1170-1176.
3. Camparo P, Vasiliu V, Molinie V et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 2008; 32: 656-670.
4. Rais-Bahrami S, Drabick JJ, De Marzo AM et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapyassociated secondary malignancy. Urology 2007; 70: 178 e3-e6.
5. Argani P, Olgac S, Tickoo SK et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007; 31: 1149-1160.
6. Bovio IM, Allan R, Oliai B et al. Xp11.2 translocation renal carcinoma with placental metastasis: a case report. Int J Surg Pathol 2009 Jan 22. [Epub ahead of print].
7. Armah HB, Parwani AV. Renal cell carcinoma in a 33-year-old male with an unusual morphology and an aggressive clinical course: possible Xp11.2 translocation. Pathology 2008; 40: 306-308.
8. Koie T, Yoneyama T, Hashimoto Y et al. An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man. Int J Urol 2009; 16: 333-335.
9. Huan C, Sashital D, Hailemariam T et al. Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin. J Biol Chem 2005; 280: 30225-30235.
10. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
11. Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 25 (Suppl): 237s (Abstr 5010).
12. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
13. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
14. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
15. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031-1039.
16. Perot C, Boccon-Gibod L, Bouvier R et al. Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytogenet 2003; 143: 93-99.
17. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
18. Stacchiotti S, Tamborini E, Marrari A et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15: 1096-1104.